Hutch News

Hutch News

Stories tagged 'pembrolizumab'

Breaking down HIV exclusions in cancer clinical trials

As an eligibility barrier cracks, a lung cancer patient gets a new lease on life

June 7, 2019 | By Fred Hutch News Service staff

A new study led by physicians at Fred Hutchinson Cancer Research Center shows that patients with HIV and one of a variety of potentially deadly cancers can be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®.

View story >


On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future

Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma

Feb. 6, 2019 | By Susan Keown / Fred Hutch News Service

More than two-thirds of people with advanced Merkel cell carcinoma are on track to survive at least two years after starting an immunotherapy drug on a landmark trial.

View story >


Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma

‘Incredibly big change’ in treatment of deadly skin cancer, new data show

June 4, 2018 | by Susan Keown / Fred Hutch News Service

Immunotherapy drugs have transformed the treatment of a deadly skin cancer, Merkel cell carcinoma. New trial results show these drugs help many patients survive much longer than would otherwise be possible.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.